Danaher Corporation (DHR)
Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y
DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.
Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript
Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference Call Participants Michael Ryskin - Bank of America Tycho Peterson - Jefferies Scott Davis - Melius Research Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Rachel Vatnsdal - JPMorgan Daniel Brennan - TD Cowen Daniel Arias - Stifel Operator My name is Chelsy, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's First Quarter 2025 Earnings Results Conference Call.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
Danaher (DHR) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.92 per share a year ago.
Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?
DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.
Exploring Analyst Estimates for Danaher (DHR) Q1 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Danaher (DHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Danaher (DHR) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds
DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.
3 Wide-Moat Dividend Stars For A Championship Portfolio
I linked investing to baseball, showing how consistency, like the A's Moneyball approach, wins long term. Steady dividend growers and low-volatility stocks outperform, especially in rocky markets. Top teams like the Dodgers now pair consistency with big spending. Similarly, investors need financially strong, wide-moat stocks with rising cash flow, durable dividends, and resilience. Moreover, I'm targeting stocks with these traits: reliable growth, low payout ratios, and recession-proof models. Like championship teams, they're built to win over time.
Danaher Corporation: A Mixed Bag Of Strength And Stagnation
Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent. DHR doesn't offer much in terms of dividend yield, but its above-average dividend growth could be attractive for dividend investors.
Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations
Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years.
Danaher: Near 5-Year Low Is A Great Entry Point
Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years.
